![Frédéric Legros](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frédéric Legros
Algemeen Directeur bij ARTHEx Biotech SL
Profiel
Frédéric Legros is currently the Executive Chairman & Chief Executive Officer at ARTHEx Biotech SL and the Chairman at Anoat Therapeutics SAS.
Previously, he worked as a Director at BliNK Biomedical SAS, Vice President-Business Development at Valneva SE from 2015 to 2017, Chief Operating Officer at Dynacure SA from 2017 to 2022, and Manager at Cnrs Innovation SA from 2003 to 2005.
Dr. Legros obtained his undergraduate degree from NEOMA Business School.
Actieve functies van Frédéric Legros
Bedrijven | Functie | Begin |
---|---|---|
ARTHEx Biotech SL
![]() ARTHEx Biotech SL Miscellaneous Commercial ServicesCommercial Services ARTHEx Biotech S.L. engages in the development of antisense RNA (ribonucleic acid) treatments against genetic diseases. It offers Anti-microRNAs for the treatment of unmet genetic diseases. The company was founded by Beatriz Llamus? and Rub?n Artero on September 27, 2019 and is headquartered in Paterna, the United Kingdom. | Algemeen Directeur | 03-05-2023 |
Anoat Therapeutics SAS
![]() Anoat Therapeutics SAS BiotechnologyHealth Technology Anoat Therapeutics SAS develops novel therapies for cystic fibrosis. The company is based in Paris, France. The French company was founded in 2023. Vincent Bischoff has been the CEO of the company since 2023. | Voorzitter | 25-03-2023 |
Eerdere bekende functies van Frédéric Legros
Bedrijven | Functie | Einde |
---|---|---|
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Operationeel Directeur | 01-10-2022 |
VALNEVA | Corporate Officer/Principal | 01-01-2017 |
Cnrs Innovation SA
![]() Cnrs Innovation SA Miscellaneous Commercial ServicesCommercial Services CNRS Innovation SA is a French company that focuses on research and innovation. The company is based in Boulogne-Billancourt, France. The company has been in the industry for over 30 years and have a team of experts who provide services to clients. The company has signed numerous operating contracts since 2012 and has supported many start-ups since 2019. The company has subsidiaries and are ultimately controlled by the Centre National de la Recherche Scientifique. | Corporate Officer/Principal | 01-10-2005 |
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Directeur/Bestuurslid | - |
Opleiding van Frédéric Legros
NEOMA Business School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
VALNEVA | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Cnrs Innovation SA
![]() Cnrs Innovation SA Miscellaneous Commercial ServicesCommercial Services CNRS Innovation SA is a French company that focuses on research and innovation. The company is based in Boulogne-Billancourt, France. The company has been in the industry for over 30 years and have a team of experts who provide services to clients. The company has signed numerous operating contracts since 2012 and has supported many start-ups since 2019. The company has subsidiaries and are ultimately controlled by the Centre National de la Recherche Scientifique. | Commercial Services |
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
ARTHEx Biotech SL
![]() ARTHEx Biotech SL Miscellaneous Commercial ServicesCommercial Services ARTHEx Biotech S.L. engages in the development of antisense RNA (ribonucleic acid) treatments against genetic diseases. It offers Anti-microRNAs for the treatment of unmet genetic diseases. The company was founded by Beatriz Llamus? and Rub?n Artero on September 27, 2019 and is headquartered in Paterna, the United Kingdom. | Commercial Services |
Anoat Therapeutics SAS
![]() Anoat Therapeutics SAS BiotechnologyHealth Technology Anoat Therapeutics SAS develops novel therapies for cystic fibrosis. The company is based in Paris, France. The French company was founded in 2023. Vincent Bischoff has been the CEO of the company since 2023. | Health Technology |